Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative ...
In a year of pivotal gastroenterology research, these 10 articles were in a class of their own, according to Dr David Johnson ...
The court set the cases of Alexion Pharmaceuticals, Inc. et al v. Amgen Canada Inc., T-1094-23 and Alexion Pharmaceuticals, ...
Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis ...
Officially Benefiting Mainland China PatientsSHANGHAI, Dec 18, 2024 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK, ...
Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...
AnaptysBio's rosnilimab faces significant competition and uncertainty. See why ANAB stock's future hinges on Feb 2025 Phase ...
Zacks.com on MSN7d
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug StudySanofi SNY and partner Teva Pharmaceuticals TEVA announced positive data from the phase IIb RELIEVE UCCD study on their ...
The drug is already approved in the EU to treat ulcerative colitis, another form of inflammatory bowel disease ...
VELSIPITY® is an innovative advanced therapy that was approved by the Pharmaceutical Administration Bureau of Macau in April 2024. It is an oral treatment taken once daily for the treatment of ...
Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...
The potential for TL1A-targeting duvakitug to impact unmet needs of patients with ulcerative colitis (UC) and Crohn’s disease (CD), and to provide anti-fibrotic effects for a host of other diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback